Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Tax

CFC rules and Russian tax residents in the pharmaceuticals sector: what in-house counsel need to know

Kristina Kornouhova · September 2026 · 11 min read

Russian CFC rules impose disclosure and tax obligations on pharma subsidiaries. In-house counsel should act before the reporting deadline. Make an enquiry.

Unlike the OECD's common approach to controlled foreign company legislation, which focuses primarily on passive income attribution, Russian CFC rules impose a broader set of obligations that extend to controlling persons, notification requirements, and active-income exemptions that do not map neatly onto the structures that pharmaceutical multinationals have historically used in the post-Soviet region. For in-house counsel at pharmaceutical companies with Russian-resident controlling shareholders or beneficial owners, understanding where Russian CFC rules apply — and where sector-specific features create additional complexity — is a practical priority, not a theoretical exercise.

Step 1. Confirm whether your structure falls within the scope of Russian CFC rules

The starting point is identifying which entities in the pharmaceutical group are captured by Russian CFC legislation. A controlled foreign company in Russian law is a foreign legal entity — or a foreign structure without legal personality — in which a Russian tax resident holds a controlling participation. The threshold is a direct or indirect shareholding above 25 per cent, or above 10 per cent where Russian residents together hold more than 50 per cent of the capital.

For pharmaceutical groups, this question is rarely straightforward. Many multinationals operating in Russia hold their local manufacturing licences, distribution rights, or intellectual property licences through intermediate holding companies incorporated in EAEU member states — Kazakhstan or Belarus, for example — or through Cyprus, the Netherlands, or Luxembourg structures that predate post-2022 restructuring exercises. Each intermediate entity must be assessed individually: Russian CFC rules look through chains of ownership, and intermediate entities that are themselves tax-resident in jurisdictions with effective information-exchange agreements with Russia may or may not qualify for the active-holding exemption. The distinction matters considerably for groups with multiple-tier pharmaceutical IP holding structures.

The controlling-person analysis also applies to individuals. A founding shareholder who remains a Russian tax resident — even if the operating company has been reorganised under foreign ownership at the entity level — may independently trigger CFC notification obligations. In-house counsel should verify the tax residency of all natural persons who hold, directly or indirectly, a material participation in any foreign entity within the pharmaceutical group.

What documents should in-house counsel prepare before CFC filing season?

Before the annual notification and profit-disclosure cycle begins, the following materials should be assembled and reviewed:

If your pharmaceutical group has not yet confirmed which foreign entities require CFC notification for the current filing cycle, make an enquiry with our Tax Controversy team: info@vetrovpartners.com |

Step 2. Apply the profit exemptions — and understand where they are unlikely to hold in the pharmaceuticals sector

Russian CFC legislation provides several profit exemptions that, if applicable, eliminate the obligation to include undistributed CFC profit in the controlling person's Russian taxable base. The most commercially significant for pharmaceutical groups are the active-income exemption and the effective-tax-rate exemption.

The active-income exemption applies where the CFC earns income from genuinely operational activities — sales of goods, provision of services, or manufacture of products — and does not predominantly earn passive income such as royalties, interest, or dividends from sub-subsidiaries. For a pharmaceutical operating subsidiary that manufactures or distributes products in its jurisdiction of incorporation, this exemption is frequently available, and Russian tax practitioners have successfully argued for it before the Federal Tax Service in the pharmaceutical context.

The difficulty arises at the level of intermediate holding and IP-holding companies. A special-purpose vehicle that holds a portfolio of pharmaceutical trade marks or patents and licenses them down to operating subsidiaries will, as a rule, earn income that is characterised as passive under Russian CFC rules — regardless of whether it employs staff or maintains a physical office. The Federal Tax Service has been increasingly active in scrutinising IP-holding structures within pharmaceutical groups, and in-house counsel should not assume that a holding company incorporated in a low-tax EAEU jurisdiction will automatically satisfy the active-income test.

Under Russian insolvency legislation precedent is largely irrelevant to this analysis — but under Tax Controversy jurisprudence from the Russian arbitrazh courts, the substance-over-form approach has been applied consistently: the economic content of the income stream determines characterisation, not the corporate label attached to the entity receiving it.

The effective-tax-rate exemption offers an alternative route: where the CFC pays tax in its jurisdiction of residence at an effective rate of at least 75 per cent of the Russian corporate rate, the undistributed profit exemption may apply. For groups with entities in EAEU member states where nominal tax rates are comparable to Russia's, this calculation requires careful attention to effective rates after local deductions and credits.

Note: Where neither exemption applies and undistributed CFC profit is included in the Russian controlling person's taxable base, late or incorrect disclosure carries material penalties under Russian tax legislation. The Federal Tax Service has increased its audit activity directed at pharmaceutical-sector CFC structures over the review period preceding this guide. Counsel should treat the notification deadline as a hard compliance date, not an administrative formality.

Step 3. Navigate the pharmaceutical sector's specific pressure points — IP structures, parallel imports, and EAEU distribution

Three sector-specific features of pharmaceutical operations in Russia create CFC-rule exposure that general-practice CFC guidance tends not to address in sufficient depth.

IP holding structures. Pharmaceutical groups frequently centralise trade mark and patent ownership in holding entities outside Russia, licensing down to local operating companies or distributors. Under Russian CFC rules, royalty income received by the holding entity constitutes passive income. If the holding entity is controlled by a Russian tax resident and does not meet the active-income exemption, those royalties are potentially includable in the controlling person's Russian taxable base. Following the 2022–2024 period of legislative adjustment, the Federal Tax Service has treated pharmaceutical IP holding structures with heightened scrutiny, particularly where the holding entity is located in a jurisdiction that has suspended or renegotiated its double-tax treaty with Russia.

Parallel import regime. Since the authorisation of parallel imports for certain pharmaceutical categories in Russia, distribution chains have become more complex — with additional intermediaries, often incorporated in EAEU member states, introduced between the foreign manufacturer and the Russian end-market. Each such intermediary must be assessed under the CFC rules. Where the intermediary is effectively controlled by a Russian-resident natural person — which occurs more frequently than corporate counsel anticipate — CFC notification obligations arise regardless of whether the intermediary was established for reasons unrelated to tax planning.

EAEU and CIS structures. Because EAEU member states share a common pharmaceutical product registration framework and coordinated market authorisation procedures, pharmaceutical groups often establish joint ventures or co-distribution structures involving partners in Kazakhstan, Belarus, or Armenia. A Russian-resident controlling person in such a structure is subject to the same CFC notification obligations as for entities incorporated in Western Europe. The active-holding exemption does not automatically apply simply because the entity is incorporated within the EAEU.

For in-house counsel managing cross-border pharmaceutical operations, the matters page provides reference examples of how the firm has advised on CFC notification and disclosure matters in comparable structures. Further analytical depth is available in our strategic considerations guide for CFC rules and Russian tax residents.

For pharmaceutical groups that have recently restructured their EAEU or IP-holding arrangements and are uncertain whether CFC notification obligations have been triggered, request our practice review: info@vetrovpartners.com |

Step 4. Prepare for Federal Tax Service audit — what a Russian tax audit of a CFC structure looks like in practice

Russian tax audits directed at CFC structures in the pharmaceutical sector typically proceed in one of two ways: as part of a broader desk audit triggered by the annual CFC notification filing, or as a dedicated field audit initiated on the basis of analytical intelligence gathered by the Federal Tax Service from financial disclosures and inter-agency data sharing.

In the desk-audit format, the Federal Tax Service will request documentation to substantiate the basis on which a profit exemption was claimed, or to verify that the profit figure disclosed matches the financial statements of the CFC. Requests commonly extend to contracts between the CFC and related parties, the transfer-pricing analysis underlying any intra-group transactions, and the economic rationale for the corporate structure. For pharmaceutical groups, transfer-pricing documentation for intra-group pharmaceutical product supply arrangements and IP licence fees is therefore a CFC-audit readiness issue as much as a standalone transfer-pricing compliance issue.

A field audit directed specifically at CFC compliance is less common but more intensive. The Federal Tax Service may request access to the controlling person's personal financial records, cross-reference Russian and foreign tax filings, and coordinate with foreign revenue authorities under automatic information-exchange arrangements. In-house counsel at pharmaceutical companies should ensure that their CFC documentation is maintained in a form that can be produced in Russian, or accompanied by certified Russian translations, within the regulatory response window.

One pattern observed in CFC enforcement trend analysis for the pharmaceutical sector is that audit requests frequently arrive simultaneously at the entity level and the controlling-person level — a coordination that in-house counsel working only at the corporate level may not anticipate.

Step 5. Establish a sustainable annual CFC compliance cycle

CFC compliance in Russia is not a one-time exercise. The obligation to notify the Federal Tax Service of controlled foreign companies arises annually, by a fixed deadline in the calendar year following the financial year in which the controlling participation was held. The obligation to disclose CFC profit — and to include undistributed profit in the controlling person's taxable base where no exemption applies — also recurs annually.

For pharmaceutical groups, the annual cycle should include the following steps as a minimum:

Review of ownership structure for any changes — new acquisitions, disposals, restructurings, or changes in the tax residency of controlling natural persons — that affect which entities require notificationCollection of financial statements from each CFC for the relevant financial year, with reconciliation to the profit figure to be disclosedAssessment of applicable profit exemptions, with fresh analysis where the CFC's income mix or operational profile has changedPreparation and filing of CFC notifications by the statutory deadlineMaintenance of a contemporaneous file of supporting documentation for each CFC and each exemption claimed, in a form suitable for production to the Federal Tax Service on request

For pharmaceutical groups operating across multiple EAEU jurisdictions, coordinating this cycle with local tax advisers in each jurisdiction — and with the Tax Controversy team advising on the Russian CFC position — is essential to avoid inconsistencies between filings that might otherwise attract audit attention.

To discuss your pharmaceutical group's annual CFC compliance cycle or to request an initial review of your current structure, make an enquiry: info@vetrovpartners.com |

Frequently asked questions

Q: How long does it take to complete a CFC notification filing in Russia for a pharmaceutical group with multiple foreign entities?

A: The preparation timeline depends on the number of entities requiring notification and the availability of financial statements. For a pharmaceutical group with three to five foreign entities, in-house teams working with experienced Russian tax counsel typically complete the substantive preparation within four to six weeks of receiving final financial statements for the relevant year. Complex multi-tier structures with IP-holding entities and intra-group royalty flows commonly require additional time for the profit-exemption analysis. Starting the process well before the statutory filing deadline — and not waiting for all group entities to finalise their accounts simultaneously — is the most reliable way to manage the timeline.

Q: What documents does the Federal Tax Service typically request when auditing a pharmaceutical company's CFC disclosures?

A: In a desk audit, the Federal Tax Service most commonly requests: the financial statements of each CFC for the relevant year; contracts between the CFC and related parties (including licence agreements for pharmaceutical intellectual property); the basis for any profit exemption claimed; and transfer-pricing documentation for intra-group transactions. For pharmaceutical-sector structures, royalty arrangements and product supply pricing between the CFC and its Russian-connected counterparties are the most frequent focus. Documentation should be maintained in Russian or with certified Russian translations ready for production.

Q: What happens if a CFC notification is filed late or a profit disclosure is incorrect?

A: Under Russian tax legislation, late filing of a CFC notification and failure to disclose CFC profit attract separate penalty regimes. The financial consequences of late or incorrect disclosure can be material, particularly where undistributed profit has not been included in the controlling person's taxable base for one or more financial years. The Federal Tax Service may also assess interest on underpaid tax. Where an error or omission is identified before an audit is commenced, a voluntary correction submitted proactively — with appropriate supporting documentation — typically results in a more predictable outcome than a correction made under audit pressure. In-house counsel who identify a compliance gap should seek Russian tax advice promptly.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry